Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé pemigatinib in FGFR-altered solid tumors
2024-512729-10-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in Nonhematologic neoplasms and Solid tumors harboring FGFR2 alterations, sponsored by Unicancer. Primary endpoint: Primary endpoint: objective response or ≥30% decrease in tumor growth kinetics at progression on treatment. Planned start Oct 2024; status: authorised.
02
Drugs
pemigatinib
03
Conditions
Nonhematologic neoplasmsSolid tumors harboring FGFR2 alterations
Beyond the preview
Go deeper on 2024-512729-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512729-10-00.